Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,943 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
Klamroth R, Hayes G, Andreeva T, Gregg K, Suzuki T, Mitha IH, Hardesty B, Shima M, Pollock T, Slev P, Oldenburg J, Ozelo MC, Stieltjes N, Castet SM, Mahlangu J, Peyvandi F, Kazmi R, Schved JF, Leavitt AD, Callaghan M, Pan-Petesch B, Quon DV, Andrews J, Trinh A, Li M, Wong WY. Klamroth R, et al. Among authors: suzuki t. Hum Gene Ther. 2022 Apr;33(7-8):432-441. doi: 10.1089/hum.2021.287. Epub 2022 Mar 16. Hum Gene Ther. 2022. PMID: 35156839 Free PMC article.
Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.
Ogiwara K, Taki M, Suzuki T, Takedani H, Matsushita T, Amano K, Matsumoto M, Nishio K, Shima M, Kasahara M, Nogami K. Ogiwara K, et al. Among authors: suzuki t. BMJ Open. 2022 Feb 17;12(2):e056922. doi: 10.1136/bmjopen-2021-056922. BMJ Open. 2022. PMID: 35177463 Free PMC article. Clinical Trial.
Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).
Nogami K, Taki M, Matsushita T, Kojima T, Oka T, Ohga S, Kawakami K, Sakai M, Suzuki T, Higasa S, Horikoshi Y, Shinozawa K, Tamura S, Yada K, Imaizumi M, Ohtsuka Y, Iwasaki F, Kobayashi M, Takamatsu J, Takedani H, Nakadate H, Matsuo Y, Matsumoto T, Fujii T, Fukutake K, Shirahata A, Yoshioka A, Shima M; J-HIS2 study group. Nogami K, et al. Among authors: suzuki t. Haemophilia. 2022 Sep;28(5):745-759. doi: 10.1111/hae.14602. Epub 2022 Jun 11. Haemophilia. 2022. PMID: 35689832
Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A. Lentz SR, et al. Among authors: suzuki t. Haemophilia. 2018 Nov;24(6):e391-e394. doi: 10.1111/hae.13617. Epub 2018 Nov 6. Haemophilia. 2018. PMID: 30402994 Clinical Trial.
The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors.
Yoshioka A, Ishii E, Ueno T, Usami I, Kobayashi M, Kobayashi R, Sotomatsu M, Shirahata A, Suzuki T, Taki M, Ishida Y, Matsushita T, Shima M, Nogami K, Sakai M, Kigasawa H, Fukutake K. Yoshioka A, et al. Among authors: suzuki t. Int J Hematol. 2015 Apr;101(4):362-8. doi: 10.1007/s12185-015-1734-z. Epub 2015 Feb 18. Int J Hematol. 2015. PMID: 25690486
[New therapeutic directions on hemophilia].
Suzuki T. Suzuki T. Rinsho Ketsueki. 2019;60(9):1275-1282. doi: 10.11406/rinketsu.60.1275. Rinsho Ketsueki. 2019. PMID: 31597853 Review. Japanese.
21,943 results
You have reached the last available page of results. Please see the User Guide for more information.